MN-DIGI-INTERNATIONAL
23.5.2022 15:02:11 CEST | Business Wire | Press release
Digi International (NASDAQ: DGII, www.digi.com ), a leading global provider of Internet of Things (IoT) connectivity products and services, today unveiled Digi IX30, an industrial-hardened cellular router solution for harsh environments. Digi IX30 provides edge intelligence in a ruggedized, industry-leading design for the highest levels of reliability and flexibility. Coupled with Digi Remote Manager ® , Digi IX30 is an all-in-one solution for applications including distribution and automation, as well as remote machine and sensor monitoring in industries such as oil and gas production, water utilities, smart cities, and outdoor signage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220523005021/en/
Digi IX30 is powered by Digi Remote Manager (Digi RM) and the Digi Accelerated Linux operating system (DAL OS). Digi RM is the command center of an intelligent network, enabling companies to efficiently configure, deploy, monitor, and manage tens of thousands of mission-critical devices and assets from a single desktop, tablet or smartphone. DAL OS, along with Digi RM, enables programmability for edge intelligence applications, interoperability for legacy serial devices/protocols, and MQTT Sparkplug B. These capabilities deliver critical connectivity between devices and sensors in the Industry 4.0 ecosystem, allowing users to experience high levels of security, control, and performance.
Ready for Public or Private Cellular Networks in ONE Solution
Digi IX30 delivers fast performance for public, private, and hybrid network deployments that support both licensed spectrum and CBRS Band 48 to enable migration between multiple networks in a single SKU. A future variant of Digi IX30 will include Anterix Band 8 along with Anterix Active certification to offer public and Anterix private cellular network support.
Battle Tested for Harsh Environments
Digi has designed its entire industrial (IX) product family to meet high-performance requirements in harsh environments with wide temperature ranges. Its Class 1, Division 2 (C1D2) and ATEX certifications makes it suitable for environments where potentially explosive gases, vapors, dust, or fibers may be present, and its DIN rail mounting design enables easy installation in field containers and cabinets.
Highest Density of I/O Options, Edge Intelligence and Complete Features for Global Deployments
Digi IX30 has the highest number of analog and digital I/O and serial ports along with rich protocol support and offers versatile integration options to manage a large of number of legacy systems from a single piece of equipment.
Digi IX30 was designed with dual Ethernet ports and GNSS, as well as support for remote sensors with four analog and four digital inputs and outputs. Leveraging its new Python programming implementation that provides interoperability with legacy serial devices/protocols, the Digi IX30 solution brings greater reliability, simplicity, and security to edge computing.
For customers who deploy and manage systems globally, Digi’s IX line provides a single SKU for high-volume global deployment, which simplifies inventory and reduces the costs of global distribution, deployment, and management.
“Digi IX30 – the newest member of our next-generation IX family of devices – builds on our widely successful legacy of industrial cellular routers,” said Sayeed Quazi, Sr. Principal Product Manager at Digi. “The ruggedized IX30, with additional compute for edge applications and additional analog and digital I/O, reduces the points of failure by eliminating the need for additional equipment. Its faster performance and LTE speeds deliver greater value through a complete, cost-effective IoT solution and significantly reduces OPEX in the most challenging deployment.”
The Digi IX30 industrial router is available immediately through global distributors.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005021/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom